Differential protein expression profiling of myocardial tissue in a mouse model of hypertrophic cardiomyopathy

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 5, 2010, Pages 1014-1022

  Lam, Lien ^a   Tsoutsman, Tatiana ^a,b   Arthur, Jonathan ^b,c   Semsarian, Christopher ^a,b,d  

^a CENTENARY INSTITUTE   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Desmin; Hypertrophic cardiomyopathy; Proteomics; Two dimensional gel electrophoresis

Indexed keywords

ALBUMIN; ALPHA ACTIN; CALCIUM BINDING PROTEIN; CARBONATE DEHYDRATASE II; CELL PROTEIN; CONTRACTILE PROTEIN; CREATINE KINASE; CYTOCHROME C OXIDASE; CYTOSKELETON PROTEIN; DESMIN; DYNEIN ADENOSINE TRIPHOSPHATASE; GELSOLIN; GLYCINE; HEAT SHOCK PROTEIN; INTERMEDIATE FILAMENT PROTEIN; MALATE DEHYDROGENASE (NADP); MYOSIN LIGHT CHAIN; PROTEIN S 100; PROTEOME; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RIBOSOME PROTEIN; SERINE; SERINE PROTEINASE INHIBITOR; SUCCINATE DEHYDROGENASE; TROPONIN I; TRYPTOPHAN HYDROXYLASE 2; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CELL STRUCTURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENERGY YIELD; GENE MUTATION; GENETIC DISORDER; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; KINESIOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHY, HYPERTROPHIC; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MICE; MICE, TRANSGENIC; MYOCARDIUM; PROTEINS; TANDEM MASS SPECTROMETRY; TROPONIN I;

MUS;

EID: 77951622128     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.08.015     Document Type: Article

References (41)

1. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995, 92:785-789.
2. Maron B.J., Shirani J., Poliac L.C., Mathenge R., Roberts W.C., Mueller F.O. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996, 276(3):199-204.
3. Chung M.W., Tsoutsman T., Semsarian C. Hypertrophic cardiomyopathy: from gene defect to clinical disease. Cell Res 2003, 13(1):9-20.
4. Lam L., Lind J., Semsarian C. Application of proteomics in cardiovascular medicine. Int. J. Cardiol 2006, 108(1):12-19.
5. Corbett J.M., Why H.J., Wheeler C.H., Richardson P.J., Archard L.C., Yacoub M.H., et al. Cardiac protein abnormalities in dilated cardiomyopathy detected by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1998, 19(11):2031-2042.
6. Warren C.M., Arteaga G.M., Rajan S., Ahmed R.P., Wieczorek D.F., Solaro R.J. Use of 2-D DIGE analysis reveals altered phosphorylation in a tropomyosin mutant (Glu54Lys) linked to dilated cardiomyopathy. Proteomics 2008, 8(1):100-105.
7. Gramolini A.O., Kislinger T., Alikhani-Koopaei R., Fong V., Thompson N.J., Isserlin R., et al. Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Mol. Cell Proteomics. 2008, 7(3):519-533.
8. Faber M.J., Agnetti G., Bezstarosti K., Lankhuizen I.M., Dalinghaus M., Guarnieri C., et al. Recent developments in proteomics: implications for the study of cardiac hypertrophy and failure. Cell Biochem. Biophys. 2006, 44(1):11-29.
9. Arnott D., O'Connell K.L., King K.L., Stults J.T. An integrated approach to proteome analysis: identification of proteins associated with cardiac hypertrophy. Anal. Biochem. 1998, 258(1):1-18.
10. Tsoutsman T., Chung J., Doolan A., Nguyen L., Williams I.A., Tu E., et al. Molecular insights from a novel cardiac troponin I mouse model of familial hypertrophic cardiomyopathy. J. Mol. Cell Cardiol. 2006, 41:623-632.
11. Nguyen L., Chung J., Lam L., Tsoutsman T., Semsarian C. Abnormal cardiac response to exercise in a murine model of familial hypertrophic cardiomyopathy. Int. J. Cardiol. 2007, 119(2):245-248.
12. Lam L., Arthur J., Semsarian C. Proteome map of the normal murine ventricular myocardium. Proteomics 2007, 7(19):3629-3633.
13. Kimura A., Harada H., Park J.E., Nishi H., Satoh M., Takahashi M., et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat. Genet. 1997, 16(4):379-382.
14. McConnell B.K., Fatkin D., Semsarian C., Jones K.A., Georgakopoulos D., Maguire C.T., et al. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res 2001, 88(4):383-389.
15. Tsoutsman T., Kelly M., Ng D.C., Tan J.E., Tu E., Lam L., et al. Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy. Circulation 2008, 117(14):1820-1831.
16. Gatlin C.L., Kleemann G.R., Hays L.G., Link A.J., Yates J.R. Protein identification at the low femtomole level from silver-stained gels using a new fritless electrospray interface for liquid chromatography-microspray and nanospray mass spectrometry. Anal. Biochem. 1998, 263(1):93-101.
17. Fink J.L., Aturaliya R.N., Davis M.J., Zhang F., Hanson K., Teasdale M.S., et al. LOCATE: a mouse protein subcellular localization database. Nucleic. Acids Res. 2006, 34(Database issue):D213-D217.
18. Thomas P.D., Campbell M.J., Kejariwal A., Mi H., Karlak B., Daverman R., et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome. Res. 2003, 13(9):2129-2141.
19. Senthil V., Chen S.N., Tsybouleva N., Halder T., Nagueh S.F., Willerson J.T., et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ. Res. 2005, 97(3):285-292.
20. Semsarian C., Ahmad I., Giewat M., Georgakopoulos D., Schmitt J.P., McConnell B.K., et al. The l-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest. 2002, 109(8):1013-1020.
21. Jullig M., Hickey A.J., Chai C.C., Skea G.L., Middleditch M.J., Costa S., et al. Is the failing heart out of fuel or a worn engine running rich? A study of mitochondria in old spontaneously hypertensive rats. Proteomics. 2008, 8(12):2556-2572.
22. Chu G., Kerr J.P., Mitton B., Egnaczyk G.F., Vazquez J.A., Shen M., et al. Proteomic analysis of hyperdynamic mouse hearts with enhanced sarcoplasmic reticulum calcium cycling. Faseb. J. 2004, 18(14):1725-1727.
23. Ashrafian H., Redwood C., Blair E., Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends. Genet 2003, 19(5):263-268.
24. Jin X., Xia L., Wang L.S., Shi J.Z., Zheng Y., Chen W.L., et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics 2006, 6(6):1948-1956.
25. Remppis A., Greten T., Schafer B.W., Hunziker P., Erne P., Katus H.A., et al. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim. Biophys. Acta. 1996, 1313(3):253-257.
26. Ehlermann P., Remppis A., Guddat O., Weimann J., Schnabel P.A., Motsch J., et al. Right ventricular upregulation of the Ca(2+) binding protein S100A1 in chronic pulmonary hypertension. Biochim. Biophys. Acta. 2000, 1500(2):249-255.
27. Trouve P., Legot S., Belikova I., Marotte F., Benevolensky D., Russo-Marie F., et al. Localization and quantitation of cardiac annexins II, V, and VI in hypertensive guinea pigs. Am. J. Physiol. 1999, 276(4 Pt 2):H1159-H1166.
28. Benevolensky D., Belikova Y., Mohammadzadeh R., Trouve P., Marotte F., Russo-Marie F., et al. Expression and localization of the annexins II, V, and VI in myocardium from patients with end-stage heart failure. Lab. Invest. 2000, 80(2):123-133.
29. Inamoto S., Murao S., Yokoyama M., Kitazawa S., Maeda S. Isoproterenol-induced myocardial injury resulting in altered S100A4 and S100A11 protein expression in the rat. Pathol. Int. 2000, 50(6):480-485.
30. Tagawa H., Koide M., Sato H. Cooper Gt. Cytoskeletal role in the contractile dysfunction of cardiocytes from hypertrophied and failing right ventricular myocardium. Proc. Assoc. Am. Physicians. 1996, 108(3):218-229.
31. Yang Q., Osinska H., Klevitsky R., Robbins J. Phenotypic deficits in mice expressing a myosin binding protein C lacking the titin and myosin binding domains. J. Mol. Cell Cardiol. 2001, 33(9):1649-1658.
32. Seguchi O., Takashima S., Yamazaki S., Asakura M., Asano Y., Shintani Y., et al. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J. Clin. Invest. 2007, 117(10):2812-2824.
33. Morano I., Bachle-Stolz C., Katus A., Ruegg J.C. Increased calcium sensitivity of chemically skinned human atria by myosin light chain kinase. Basic Res. Cardiol. 1988, 83(4):350-359.
34. White M.Y., Cordwell S.J., McCarron H.C., Prasan A.M., Craft G., Hambly B.D., et al. Proteomics of ischemia/reperfusion injury in rabbit myocardium reveals alterations to proteins of essential functional systems. Proteomics 2005, 5(5):1395-1410.
35. van der Velden J., Papp Z., Boontje N.M., Zaremba R., de Jong J.W., Janssen P.M., et al. The effect of myosin light chain 2 dephosphorylation on Ca2+-sensitivity of force is enhanced in failing human hearts. Cardiovasc. Res 2003, 57(2):505-514.
36. Faber M.J., Dalinghaus M., Lankhuizen I.M., Bezstarosti K., Dekkers D.H., Duncker D.J., et al. Proteomic changes in the pressure overloaded right ventricle after 6 weeks in young rats: correlations with the degree of hypertrophy. Proteomics 2005, 5(10):2519-2530.
37. Heling A., Zimmermann R., Kostin S., Maeno Y., Hein S., Devaux B., et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ. Res 2000, 86(8):846-853.
38. Hwang D.M., Dempsey A.A., Wang R.X., Rezvani M., Barrans J.D., Dai K.S., et al. A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. Circulation 1997, 96(12):4146-4203.
39. Di Somma S., Marotta M., Salvatore G., Cudemo G., Cuda G., De Vivo F., et al. Changes in myocardial cytoskeletal intermediate filaments and myocyte contractile dysfunction in dilated cardiomyopathy: an in vivo study in humans. Heart 2000, 84(6):659-667.
40. Monreal G., Nicholson L.M., Han B., Joshi M.S., Phillips A.B., Wold L.E., et al. Cytoskeletal remodeling of desmin is a more accurate measure of cardiac dysfunction than fibrosis or myocyte hypertrophy. Life Sci. 2008, 83(23-24):786-794.
41. Milner D.J., Taffet G.E., Wang X., Pham T., Tamura T., Hartley C., et al. The absence of desmin leads to cardiomyocyte hypertrophy and cardiac dilation with compromised systolic function. J Mol. Cell Cardiol. 1999, 31(11):2063-2076.